Navigation Links
40 Percent of Community Pharmacists Dispensed Off-label Drug

Forty per cent of community pharmacists have dispensed an off-label drug to a child in the last month, according to research published in the July issue of the British Journal of Clinical Pharmacology .

And although 78 per cent said they would tell a family doctor that the prescription they had written would have to be dispensed off-label outside the terms of the drugs product license only 66 per cent felt they had a similar responsibility to inform the childs parents.

Pharmacists said the most common off-label dispensing of prescribed and over-the-counter medicines involved giving a drug to a child who was younger than the recommended minimum age for the drug or giving them higher than the recommended dose.

Just under 500 community pharmacists, with wide-ranging experience and post-registration education, took part in the research, carried out by the Department of Medicine and Therapeutics at the University of Aberdeen, UK.

The community pharmacists who responded to the questionnaire appeared to be aware of and concerned by - the issues surrounding off-label prescribing to children says co-author Dr James McLay.

What did concern us was that only 40 per cent of pharmacists said they had dispensed off-label medicines to children in the month before the survey.Having reviewed primary care prescribing levels, this 40 per cent figure was lower than expected and leads us to conclude that many pharmacists may not realise that they are dispensing off-label.

And a third said they didnt feel they had a responsibility to inform parents of off-label prescribing, possibly because this could suggest criticism of the family doctor who prescribed the drug.

The researchers also found that most of the 482 randomly-selected pharmacists gained their knowledge of off-label dispensing through work experience rather than education.

While all licensed medicines used to treat childr
'"/>




Page: 1 2

Related medicine news :

1. 45 Percent Of Errors In Cancer Diagnosis Harm The Patient
2. Births Out Of Wedlock Increased To 42 Percent in 2004 in the UK
3. Community Dentists To Receive 10 Percent Salary Boost
4. Almost 30 Percent Dentists Refuse To Sign NHS Contracts
5. Polyunsaturated Fats And Vitamin E Cut MND Risk By 60 Percent
6. More Than 50 Percent Indians Aged Over 40 Have Diabetes, High Blood Pressure
7. Around 20 Percent Take-Out Foods Are Unhygienic
8. 47 Percent Children Suffer from Malnutrition: Survey
9. About 5 Percent of Adults with Insomnia Use Alternative Therapies
10. A Laboratory Filtration System Kills 100 Percent Of Dangerous Microbes In Water
11. 11 Percent Increase of Addictive Nicotine in Cigarettes: Report
Post Your Comments:
Breaking Medicine Technology:Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 2Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 3Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7Royalty Pharma Announces that Alexander von Perfall Joins Management Team 24th BTLtec Conference on 24 25 Sep in Graz Austria features Biomass to Liquids Innovators Sharing Updates on Pyrolysis and Gasification Technologies 13115 14th BTLtec Conference on 24 25 Sep in Graz Austria features Biomass to Liquids Innovators Sharing Updates on Pyrolysis and Gasification Technologies 13115 24th BTLtec Conference on 24 25 Sep in Graz Austria features Biomass to Liquids Innovators Sharing Updates on Pyrolysis and Gasification Technologies 13115 3HealthCare Partners of Nevada and Fremont Medical Center Join Forces 52190 1HealthCare Partners of Nevada and Fremont Medical Center Join Forces 52190 2Tiffany Diamond Eternity Bands and Cartier 26apos 3BLove 26apos 3B Rings 3A Beladora Announces Sharp Wedding Jewelry Sales Increase 52188 1Tiffany Diamond Eternity Bands and Cartier 26apos 3BLove 26apos 3B Rings 3A Beladora Announces Sharp Wedding Jewelry Sales Increase 52188 2Tiffany Diamond Eternity Bands and Cartier 26apos 3BLove 26apos 3B Rings 3A Beladora Announces Sharp Wedding Jewelry Sales Increase 52188 3